November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Peter Pisters: Launching the Institute for Cell Therapy Discovery and Innovation at MD Anderson Cancer Center
Nov 9, 2024, 15:17

Peter Pisters: Launching the Institute for Cell Therapy Discovery and Innovation at MD Anderson Cancer Center

Peter Pisters, President of The University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:

“Today, we at MD Anderson Cancer Center were thrilled to launch the Institute for Cell Therapy Discovery and Innovation, which aims to lead the world in developing and advancing cell therapies for patients in need.

By bringing together top scientists and clinicians, we look forward to uncovering new insights in immunology and cell engineering, fueling the creation of transformational new treatments for cancer, autoimmune diseases, infections and other conditions.”

Katy Rezvani, Sally Cooper Murray Chair in Cancer Research at MD Anderson Cancer Center, shared this post on X, adding:

“Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases.”

Peter Pisters: Launching the Institute for Cell Therapy Discovery and Innovation at MD Anderson Cancer Center

More posts featuring Peter Pisters and Katy Rezvani.

Peter Pisters leads The University of Texas MD Anderson Cancer Center, driving research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine, and rehabilitation medicine. He contributes to academic journals like the Journal of Clinical Oncology and Surgery, and reviews for various publications. His research, concentrated on sarcomas, GI cancers, and other malignancies.

Katy Rezvani is the Sally Cooper Murray Chair in Cancer Research at MD Anderson Cancer Center. Previously, she was Professor of Medicine and Chief of Section of Cellular Therapy at MD Anderson. Dr. Rezvani’s research focuses on enhancing natural killer (NK) cell function against leukemia, utilizing genetic engineering techniques. Her work has led to funded Phase I/II trials in leukemia and lymphoma immunotherapy.